These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 32193288)

  • 1. The Interplay between Slow-Cycling, Chemoresistant Cancer Cells and Fibroblasts Creates a Proinflammatory Niche for Tumor Progression.
    Cho J; Lee HJ; Hwang SJ; Min HY; Kang HN; Park AY; Hyun SY; Sim JY; Lee HJ; Jang HJ; Suh YA; Hong S; Shin YK; Kim HR; Lee HY
    Cancer Res; 2020 Jun; 80(11):2257-2272. PubMed ID: 32193288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reverse of non-small cell lung cancer drug resistance induced by cancer-associated fibroblasts via a paracrine pathway.
    Zhang Q; Yang J; Bai J; Ren J
    Cancer Sci; 2018 Apr; 109(4):944-955. PubMed ID: 29383798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of Distinct Populations of Carcinoma-Associated Fibroblasts from Non-Small Cell Lung Carcinoma Reveals a Role for ST8SIA2 in Cancer Cell Invasion.
    Hao J; Zeltz C; Pintilie M; Li Q; Sakashita S; Wang T; Cabanero M; Martins-Filho SN; Wang DY; Pasko E; Venkat K; Joseph J; Raghavan V; Zhu CQ; Wang YH; Moghal N; Tsao MS; Navab R
    Neoplasia; 2019 May; 21(5):482-493. PubMed ID: 30978569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated expression of BIRC6 protein in non-small-cell lung cancers is associated with cancer recurrence and chemoresistance.
    Dong X; Lin D; Low C; Vucic EA; English JC; Yee J; Murray N; Lam WL; Ling V; Lam S; Gout PW; Wang Y
    J Thorac Oncol; 2013 Feb; 8(2):161-70. PubMed ID: 23287853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemotherapy-induced PDL-1 expression in cancer-associated fibroblasts promotes chemoresistance in NSCLC.
    Heenatigala Palliyage G; Samart P; Bobbala S; Rojanasakul LW; Coyle J; Martin K; Callery PS; Rojanasakul Y
    Lung Cancer; 2023 Jul; 181():107258. PubMed ID: 37245409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status.
    Formisano L; D'Amato V; Servetto A; Brillante S; Raimondo L; Di Mauro C; Marciano R; Orsini RC; Cosconati S; Randazzo A; Parsons SJ; Montuori N; Veneziani BM; De Placido S; Rosa R; Bianco R
    Oncotarget; 2015 Sep; 6(28):26090-103. PubMed ID: 26325669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. JAK1/STAT3 Activation through a Proinflammatory Cytokine Pathway Leads to Resistance to Molecularly Targeted Therapy in Non-Small Cell Lung Cancer.
    Shien K; Papadimitrakopoulou VA; Ruder D; Behrens C; Shen L; Kalhor N; Song J; Lee JJ; Wang J; Tang X; Herbst RS; Toyooka S; Girard L; Minna JD; Kurie JM; Wistuba II; Izzo JG
    Mol Cancer Ther; 2017 Oct; 16(10):2234-2245. PubMed ID: 28729401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of Src kinase inhibition induced by dasatinib in non-small cell lung cancer cell lines treated with cisplatin.
    Ceppi P; Papotti M; Monica V; Lo Iacono M; Saviozzi S; Pautasso M; Novello S; Mussino S; Bracco E; Volante M; Scagliotti GV
    Mol Cancer Ther; 2009 Nov; 8(11):3066-74. PubMed ID: 19861409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The ATF6-EGF Pathway Mediates the Awakening of Slow-Cycling Chemoresistant Cells and Tumor Recurrence by Stimulating Tumor Angiogenesis.
    Cho J; Min HY; Pei H; Wei X; Sim JY; Park SH; Hwang SJ; Lee HJ; Hong S; Shin YK; Lee HY
    Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32630838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RGS2-mediated translational control mediates cancer cell dormancy and tumor relapse.
    Cho J; Min HY; Lee HJ; Hyun SY; Sim JY; Noh M; Hwang SJ; Park SH; Boo HJ; Lee HJ; Hong S; Park RW; Shin YK; Hung MC; Lee HY
    J Clin Invest; 2021 Jan; 131(1):. PubMed ID: 33393490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rhodomycin A, a novel Src-targeted compound, can suppress lung cancer cell progression via modulating Src-related pathways.
    Lai YH; Chen MH; Lin SY; Lin SY; Wong YH; Yu SL; Chen HW; Yang CH; Chang GC; Chen JJ
    Oncotarget; 2015 Sep; 6(28):26252-65. PubMed ID: 26312766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extracellular vesicles of carcinoma-associated fibroblasts creates a pre-metastatic niche in the lung through activating fibroblasts.
    Kong J; Tian H; Zhang F; Zhang Z; Li J; Liu X; Li X; Liu J; Li X; Jin D; Yang X; Sun B; Guo T; Luo Y; Lu Y; Lin B; Liu T
    Mol Cancer; 2019 Dec; 18(1):175. PubMed ID: 31796058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer-associated fibroblasts promote epithelial-mesenchymal transition and EGFR-TKI resistance of non-small cell lung cancers via HGF/IGF-1/ANXA2 signaling.
    Yi Y; Zeng S; Wang Z; Wu M; Ma Y; Ye X; Zhang B; Liu H
    Biochim Biophys Acta Mol Basis Dis; 2018 Mar; 1864(3):793-803. PubMed ID: 29253515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting nuclear receptors in cancer-associated fibroblasts as concurrent therapy to inhibit development of chemoresistant tumors.
    Chan JSK; Sng MK; Teo ZQ; Chong HC; Twang JS; Tan NS
    Oncogene; 2018 Jan; 37(2):160-173. PubMed ID: 28892046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a chemoresistant orthotopic human nonsmall cell lung carcinoma model in nude mice: analyses of tumor heterogenity in relation to the immunohistochemical levels of expression of cyclooxygenase-2, ornithine decarboxylase, lung-related resistance protein, prostaglandin E synthetase, and glutathione-S-transferase-alpha (GST)-alpha, GST-mu, and GST-pi.
    Mathieu A; Remmelink M; D'Haene N; Penant S; Gaussin JF; Van Ginckel R; Darro F; Kiss R; Salmon I
    Cancer; 2004 Oct; 101(8):1908-18. PubMed ID: 15386340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer-associated fibroblasts treated with cisplatin facilitates chemoresistance of lung adenocarcinoma through IL-11/IL-11R/STAT3 signaling pathway.
    Tao L; Huang G; Wang R; Pan Y; He Z; Chu X; Song H; Chen L
    Sci Rep; 2016 Dec; 6():38408. PubMed ID: 27922075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gallic acid inhibition of Src-Stat3 signaling overcomes acquired resistance to EGF receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer.
    Phan AN; Hua TN; Kim MK; Vo VT; Choi JW; Kim HW; Rho JK; Kim KW; Jeong Y
    Oncotarget; 2016 Aug; 7(34):54702-54713. PubMed ID: 27419630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective Cox-2 inhibitor celecoxib induces epithelial-mesenchymal transition in human lung cancer cells via activating MEK-ERK signaling.
    Wang ZL; Fan ZQ; Jiang HD; Qu JM
    Carcinogenesis; 2013 Mar; 34(3):638-46. PubMed ID: 23172668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lung cancer-derived galectin-1 contributes to cancer associated fibroblast-mediated cancer progression and immune suppression through TDO2/kynurenine axis.
    Hsu YL; Hung JY; Chiang SY; Jian SF; Wu CY; Lin YS; Tsai YM; Chou SH; Tsai MJ; Kuo PL
    Oncotarget; 2016 May; 7(19):27584-98. PubMed ID: 27050278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conophylline suppresses pancreatic cancer desmoplasia and cancer-promoting cytokines produced by cancer-associated fibroblasts.
    Ishii N; Araki K; Yokobori T; Hagiwara K; Gantumur D; Yamanaka T; Handa T; Tsukagoshi M; Igarashi T; Watanabe A; Kubo N; Harimoto N; Masamune A; Umezawa K; Kuwano H; Shirabe K
    Cancer Sci; 2019 Jan; 110(1):334-344. PubMed ID: 30353606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.